We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Insufficient Interleukin-35 Leads to Type I Diabetes in Mouse Models

By LabMedica International staff writers
Posted on 10 Aug 2015
Print article
Image: A representative image of islets from diabetic mice, which did not receive IL-35 (left) and received IL-35 (right). The brown color represents insulin producing beta cells. New research showed progress in the use of the anti-inflammatory cytokine for treatment of Type I diabetes (Photo courtesy of Dr. Kailash Singh, Uppsala University).
Image: A representative image of islets from diabetic mice, which did not receive IL-35 (left) and received IL-35 (right). The brown color represents insulin producing beta cells. New research showed progress in the use of the anti-inflammatory cytokine for treatment of Type I diabetes (Photo courtesy of Dr. Kailash Singh, Uppsala University).
Diabetes researchers have linked onset of the disease to abnormally low levels of the anti-inflammatory cytokine interleukin-35 (IL-35), which is produced by regulatory T (Treg) cells to suppress autoimmune and inflammatory responses.

Investigators at Uppsala University (Sweden) used two mouse models to study the role of IL-35 in Type I diabetes (Tid). The first model consisted of mice made diabetic by multiple injections of low doses of the drug streptozotocin (MLDSTZ mice), while the second consisted of mice from the non-obese diabetic mouse (NOD) line.

The investigators studied the kinetics of Treg cell response in the MLDSTZ model and measured the levels of IL-35 in human T1D patients. They found that Treg cells were increased in MLDSTZ mice. However, the Treg cells showed a decreased production of anti-inflammatory cytokines (IL-10, IL-35, TGF-beta) and increased production of pro-inflammatory cytokines (IFN-gamma, IL-2, IL-17), indicating a phenotypic shift of Treg cells under T1D conditions.

Results published in the July 30, 2015, online edition of the journal Scientific Reports revealed that administration of IL-35 effectively prevented development of T1d in MLDSTZ mice and counteracted established T1D in this model, seemingly by induction of IL-35 production in Treg cells, thus reversing the phenotypic shift of the Treg cells. In addition, IL-35 administration reversed established hyperglycemia in the NOD mouse model of T1D. Moreover, circulating IL-35 levels were decreased in human T1D patients compared to healthy controls.

"To the best of our knowledge, we are the first to show that IL-35 can reverse established Type I diabetes in two different mouse models and that the concentration of the particular cytokine is lower in Type I diabetes patients than in healthy individuals. Also, we are providing an insight into a novel mechanism: how immune regulatory T cells change their fate under autoimmune conditions," said first author Dr. Kailash Singh, a graduate researcher in medical cell biology at Uppsala University.

Related Links:

Uppsala University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.